Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,039 | $4,013 | $4,737 | $1,078 |
| % Growth | -74.1% | -15.3% | 339.4% | – |
| Cost of Goods Sold | $2,785 | $0 | $0 | $0 |
| Gross Profit | -$1,746 | $4,013 | $4,737 | $1,078 |
| % Margin | -168% | 100% | 100% | 100% |
| R&D Expenses | $240,156 | $168,527 | $130,225 | $84,255 |
| G&A Expenses | $99,737 | $58,094 | $42,394 | $24,525 |
| SG&A Expenses | $99,737 | $58,094 | $42,394 | $24,525 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,785 | $0 | $0 | $0 |
| Operating Expenses | $337,108 | $226,621 | $172,619 | $108,780 |
| Operating Income | -$338,854 | -$222,608 | -$167,882 | -$107,702 |
| % Margin | -32,613.5% | -5,547.2% | -3,544.1% | -9,990.9% |
| Other Income/Exp. Net | $40,446 | $8,079 | $3,964 | $61 |
| Pre-Tax Income | -$298,408 | -$214,529 | -$163,918 | -$107,641 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$298,408 | -$214,529 | -$163,918 | -$107,641 |
| % Margin | -28,720.7% | -5,345.9% | -3,460.4% | -9,985.3% |
| EPS | -3.69 | -3.69 | -3.15 | -2.8 |
| % Growth | 0% | -17.1% | -12.5% | – |
| EPS Diluted | -3.69 | -3.69 | -3.15 | -2.8 |
| Weighted Avg Shares Out | 80,783 | 58,071 | 51,982 | 38,436 |
| Weighted Avg Shares Out Dil | 80,783 | 58,071 | 51,982 | 38,436 |
| Supplemental Information | – | – | – | – |
| Interest Income | $41,435 | $13,436 | $4,317 | $157 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,785 | $1,098 | $983 | $922 |
| EBITDA | -$336,069 | -$221,510 | -$166,899 | -$106,780 |
| % Margin | -32,345.4% | -5,519.8% | -3,523.3% | -9,905.4% |